Target intelligence / Profile preview

Gut microbiota, immune pathways, and pathogens

Molecular classification
Biological system, Other
01

Overview

The term "Gut microbiota, immune pathways, and pathogens" describes a complex physiological system rather than a single molecular target. This axis encompasses the interactions between the trillions of commensal microorganisms in the gut, the host's innate and adaptive immune systems, and potential infectious agents (Belkaid & Hand, 2014, Science). The microbiota is essential for the maturation of the immune system and the maintenance of the intestinal epithelial barrier, primarily through the production of metabolites like short-chain fatty acids (Round & Mazmanian, 2009, Nature Reviews Immunology). Disruptions in this ecosystem, known as dysbiosis, are linked to the pathogenesis of inflammatory bowel disease, metabolic disorders, and susceptibility to pathogens like Clostridioides difficile (Pickard et al., 2017, Immunological Reviews). While not a single receptor or enzyme, this system is therapeutically modulated via probiotics, prebiotics, and fecal microbiota transplantation to restore homeostasis (Khoruts & Sadowsky, 2016, Gastroenterology). Furthermore, the composition of the gut microbiome has emerged as a critical factor in determining the efficacy of systemic therapies, including cancer immunotherapies (Gopalakrishnan et al., 2018, Science).

Other names
Gut-immune axisMicrobiome-immune system interactionHost-microbe-pathogen interface
02

Mechanism of action

Modulation of the microbial ecosystem to restore immune homeostasis, strengthen the intestinal barrier, and provide competitive exclusion of pathogens (Khoruts & Sadowsky, 2016, Gastroenterology).

03

Biological functions

Immune responseMetabolismPathogen defenseIntestinal barrier maintenanceOther
04

Disease associations

InflammationInfectionCancerAutoimmune diseaseMetabolic syndromeOther
05

Safety considerations

Risk of bacteremia or systemic infectionTransfer of antibiotic resistance genesVariable patient response to microbiome modulationLack of standardized regulatory frameworks for live biotherapeutics
06

Interacting drugs

Probiotics

4 more in the full profile.

07

Biomarkers

Microbial alpha diversityShort-chain fatty acid levelsFecal calprotectin16S rRNA sequencing profiles

Beyond the preview

Go deeper on Gut microbiota, immune pathways, and pathogens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota, immune pathways, and pathogens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call